Cadherin-17 as a target for the immunoPET of adenocarcinoma.
Samantha DelaneyOuti KeinänenDennis LamAndrew L WolfeTakao HamakuboBrian M ZeglisPublished in: European journal of nuclear medicine and molecular imaging (2024)
Zr]Zr-DFO-D2101 is a highly promising probe for the non-invasive visualization of CDH17 expression in PDAC. We contend that this radioimmunoconjugate could have a significant impact on the clinical management of patients with both PDAC and gastrointestinal adenocarcinoma, most likely as a theranostic imaging tool in support of CDH17-targeted therapies.